FINWIRES · TerminalLIVE
FINWIRES

CSPC-Licensed Oropharyngeal Cancer Drug Cleared for U.S. Registrational Trial

By

CSPC Pharmaceutical (HKG:1093) said Corbus Pharmaceuticals has received U.S. FDA clearance to begin a registrational trial of CRB-701 (SYS6002), which it is developing under license from CSPC, for second-line treatment of oropharyngeal squamous cell carcinoma.

The TEMPO-1 study will evaluate the antibody-drug conjugate against the investigator's choice of capecitabine, cetuximab, or docetaxel, with objective response rate and overall survival as the primary endpoints, according to a Wednesday filing with the Hong Kong bourse.

Corbus expects to begin patient enrollment in the third quarter of 2026.

Related Articles

Asia

Jinhui Signs Sale-and-Leaseback Deals for Two Bulk Carriers

Jinhui (HKG:0137) has entered into sale-and-leaseback arrangements for two bulk carriers under construction, according to a Tuesday Hong Kong bourse filing.The company will sell each vessel to a unit of ICBC Financial Leasing for up to $18 million and lease them back under separate five-year bareboat charter agreements.The vessels, each with a deadweight of about 64,500 metric tonnes, are expected to be delivered in February and March 2028.

HKG:0137
Asia

BOE Technology Controlling Shareholder to Boost Ownership

BOE Technology (SHE:000725) said its controlling shareholder, Beijing Electronics, plans to purchase company shares worth 500 million yuan to 1 billion yuan over the next six months, according to a Wednesday filing with the Shenzhen bourse.

SHE:000725
Asia

CapitaLand India Trust Spends 30% of Private Placement Proceeds

CapitaLand India Trust (SGX:CY6U) has used SG$45.6 million, representing 30.4% of the gross proceeds of the private placement conducted earlier this year, according to a Wednesday filing to the Singapore stock exchange.Of the SG$100 million earmarked to part fund the ongoing development and construction as part of its acquisition of Building 1 of Ebisu in Bangalore, India, the manager used SG$37.3 million.The company also used SG$5.7 million of the SG$47.4 million allotted to part fund the ongoing development and construction of and acquisition of an office project in Bangalore from Maia Estates Offices.It also used SG$2.6 million to pay all the fees and expenses tied to the private placement.The company's shares were up nearly 2% in recent trade.

SGX:CY6U